A Clinical Trial Comparing Glycaemic Control and Safety of Insulin Degludec/Liraglutide (IDegLira) Versus Insulin Glargine (IGlar) as add-on Therapy to SGLT2i in Subjects With Type 2 Diabetes Mellitus (DUALTM IX)

A Clinical Trial Comparing Glycaemic Control and Safety of Insulin Degludec/Liraglutide (IDegLira) Versus Insulin Glargine (IGlar) as add-on Therapy to SGLT2i in Subjects With Type 2 Diabetes Mellitus. DUALTM IX - Add-on to SGLT2i

This trial is conducted globally. The aim of this trial is comparing glycaemic control and safety of insulin degludec/liraglutide (IDegLira) versus insulin glargine (IGlar) as add-on therapy to SGLT2i (sodium-glucose cotransporter 2 inhibitors) in subjects with type 2 diabetes mellitus.

Study Overview

• Status: Completed
• Conditions: Diabetes Mellitus, Type 2; Diabetes
• Intervention / Treatment: Drug: insulin degludec/liraglutide; Drug: insulin glargine

• Study Type: Interventional
• Enrollment (Actual): 420
• Phase: Phase 3

Contacts and Locations

Study Locations

• Argentina
  • Buenos Aires, Argentina, C1425AGC
    • Novo Nordisk Investigational Site
  • Caba, Argentina, C1180AAX
    • Novo Nordisk Investigational Site
  • Caba, Argentina, C1120AAC
    • Novo Nordisk Investigational Site
  • Mendoza, Argentina, 5500
    • Novo Nordisk Investigational Site
• Canada
  • Manitoba
    • Winnipeg, Manitoba, Canada, R2V 4W3
      • Novo Nordisk Investigational Site
  • New Brunswick
    • Moncton, New Brunswick, Canada, E1G 1A7
      • Novo Nordisk Investigational Site
  • Ontario
    • Burlington, Ontario, Canada, L7M 4Y1
      • Novo Nordisk Investigational Site
    • London, Ontario, Canada, N6G 2M1
      • Novo Nordisk Investigational Site
    • Smiths Falls, Ontario, Canada, K7A 4W8
      • Novo Nordisk Investigational Site
  • Quebec
    • Montreal, Quebec, Canada, H4A 3T2
      • Novo Nordisk Investigational Site
• Finland
  • Helsinki, Finland, 00100
    • Novo Nordisk Investigational Site
  • Lahti, Finland, 15110
    • Novo Nordisk Investigational Site
  • Oulu, Finland, FI-90220
    • Novo Nordisk Investigational Site
  • Rovaniemi, Finland, 96400
    • Novo Nordisk Investigational Site
  • Tampere, Finland, 33520
    • Novo Nordisk Investigational Site
  • Turku, Finland, 20520
    • Novo Nordisk Investigational Site
• Hungary
  • Budapest, Hungary, 1042
    • Novo Nordisk Investigational Site
  • Debrecen, Hungary, 4043
    • Novo Nordisk Investigational Site
  • Komarom, Hungary, 2900
    • Novo Nordisk Investigational Site
  • Salgótarján, Hungary, 3100
    • Novo Nordisk Investigational Site
  • Szekszárd, Hungary, 7100
    • Novo Nordisk Investigational Site
  • Zalaegerszeg, Hungary, 8900
    • Novo Nordisk Investigational Site
• India
  • New Delhi, India, 110001
    • Novo Nordisk Investigational Site
  • Andhra Pradesh
    • Hyderbad, Andhra Pradesh, India, 500 012
      • Novo Nordisk Investigational Site
  • Madhya Pradesh
    • Bhopal, Madhya Pradesh, India, 462037
      • Novo Nordisk Investigational Site
  • Maharashtra
    • Pune, Maharashtra, India, 411040
      • Novo Nordisk Investigational Site
  • Punjab
    • Ludhiana, Punjab, India, 141001
      • Novo Nordisk Investigational Site
  • Rajasthan
    • Jaipur, Rajasthan, India, 302004
      • Novo Nordisk Investigational Site
  • Tamil Nadu
    • Chennai, Tamil Nadu, India, 600086
      • Novo Nordisk Investigational Site
    • Chennai, Tamil Nadu, India, 600029
      • Novo Nordisk Investigational Site
  • Uttar Pradesh
    • Varanasi, Uttar Pradesh, India, 221105
      • Novo Nordisk Investigational Site
  • West Bengal
    • Kolkata, West Bengal, India, 700054
      • Novo Nordisk Investigational Site
• Russian Federation
  • Barnaul, Russian Federation, 656043
    • Novo Nordisk Investigational Site
  • Moscow, Russian Federation, 123423
    • Novo Nordisk Investigational Site
  • Novosibirsk, Russian Federation, 630047
    • Novo Nordisk Investigational Site
  • Saint-Petersburg, Russian Federation, 194358
    • Novo Nordisk Investigational Site
  • Saint-Petersburg, Russian Federation, 191119
    • Novo Nordisk Investigational Site
  • Saint-Petesburg, Russian Federation, 195257
    • Novo Nordisk Investigational Site
  • St. Petersburg, Russian Federation, 194354
    • Novo Nordisk Investigational Site
• Slovakia
  • Kosice, Slovakia, 040 01
    • Novo Nordisk Investigational Site
  • Lucenec, Slovakia, 984 01
    • Novo Nordisk Investigational Site
  • Nitra, Slovakia, 94901
    • Novo Nordisk Investigational Site
  • Presov, Slovakia, 080 01
    • Novo Nordisk Investigational Site
  • Trnava, Slovakia, 91701
    • Novo Nordisk Investigational Site
• Slovenia
  • Celje, Slovenia, SI-3000
    • Novo Nordisk Investigational Site
  • Koper, Slovenia, SI-6000
    • Novo Nordisk Investigational Site
  • Kranj, Slovenia, 4000
    • Novo Nordisk Investigational Site
  • Murska Sobota, Slovenia, SI-9000
    • Novo Nordisk Investigational Site
  • Trbovlje, Slovenia, 1420
    • Novo Nordisk Investigational Site
• Spain
  • Almería, Spain, 04001
    • Novo Nordisk Investigational Site
  • Antequera, Spain, 29200
    • Novo Nordisk Investigational Site
  • Barcelona, Spain, 08035
    • Novo Nordisk Investigational Site
  • Boadilla del Monte, Spain, 28660
    • Novo Nordisk Investigational Site
  • Sevilla, Spain, 41003
    • Novo Nordisk Investigational Site
  • Sevilla, Spain, 41009
    • Novo Nordisk Investigational Site
  • Villamartin, Spain, 11650
    • Novo Nordisk Investigational Site
• Switzerland
  • Baden, Switzerland, 5400
    • Novo Nordisk Investigational Site
  • Genève 14, Switzerland, 1211
    • Novo Nordisk Investigational Site
  • Luzern 16, Switzerland, 6000
    • Novo Nordisk Investigational Site
  • Olten, Switzerland, 4600
    • Novo Nordisk Investigational Site
  • Schaffhausen, Switzerland, 8208
    • Novo Nordisk Investigational Site
  • Winterthur, Switzerland, 8400
    • Novo Nordisk Investigational Site
  • Zollikerberg, Switzerland, 8125
    • Novo Nordisk Investigational Site
  • Zürich, Switzerland, 8091
    • Novo Nordisk Investigational Site
• United States
  • Arizona
    • Glendale, Arizona, United States, 85308
      • Novo Nordisk Investigational Site
  • California
    • La Jolla, California, United States, 92037
      • Novo Nordisk Investigational Site
    • Mission Viejo, California, United States, 92691
      • Novo Nordisk Investigational Site
    • Northridge, California, United States, 91325
      • Novo Nordisk Investigational Site
    • Palm Springs, California, United States, 92262
      • Novo Nordisk Investigational Site
    • San Ramon, California, United States, 94583
      • Novo Nordisk Investigational Site
  • Florida
    • Boynton Beach, Florida, United States, 33472
      • Novo Nordisk Investigational Site
    • Chiefland, Florida, United States, 32626
      • Novo Nordisk Investigational Site
  • Illinois
    • Skokie, Illinois, United States, 60077
      • Novo Nordisk Investigational Site
  • Indiana
    • Avon, Indiana, United States, 46123
      • Novo Nordisk Investigational Site
  • Maryland
    • Rockville, Maryland, United States, 20852
      • Novo Nordisk Investigational Site
  • Nevada
    • Las Vegas, Nevada, United States, 89118
      • Novo Nordisk Investigational Site
  • New Jersey
    • Teaneck, New Jersey, United States, 07666
      • Novo Nordisk Investigational Site
  • New York
    • Albany, New York, United States, 12206
      • Novo Nordisk Investigational Site
    • West Seneca, New York, United States, 14224
      • Novo Nordisk Investigational Site
  • North Carolina
    • Whiteville, North Carolina, United States, 28472
      • Novo Nordisk Investigational Site
  • Ohio
    • Mason, Ohio, United States, 45040-6815
      • Novo Nordisk Investigational Site
  • South Carolina
    • Greer, South Carolina, United States, 29651
      • Novo Nordisk Investigational Site
  • Tennessee
    • Bristol, Tennessee, United States, 37620-7352
      • Novo Nordisk Investigational Site
  • Texas
    • Austin, Texas, United States, 78731
      • Novo Nordisk Investigational Site
    • Houston, Texas, United States, 77081
      • Novo Nordisk Investigational Site
    • Longview, Texas, United States, 75605
      • Novo Nordisk Investigational Site
    • San Antonio, Texas, United States, 78228-3419
      • Novo Nordisk Investigational Site
  • Wisconsin
    • Kenosha, Wisconsin, United States, 53144
      • Novo Nordisk Investigational Site

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years and older (Adult, Older Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

Description

Inclusion Criteria: - Male or female, age at least 18 years at the time of signing informed consent - Subjects diagnosed (clinically) with type 2 diabetes mellitus - HbA1c 7.0-11.0% [53-97 mmol/mol] (both inclusive) by central laboratory analysis - Body mass index (BMI) equal to or above 20 kg/m^2 and below 40 kg/m^2 - Insulin naïve subjects; however short term insulin treatment for a maximum of 14 days prior to the day of screening is allowed, as well as prior insulin treatment for gestational diabetes - A stable daily dose for at least 90 days prior to the day of screening of any SGLT2i in monotherapy or in combination with metformin ± DPP4i ± pioglitazone. Use of pioglitazone is not allowed in subjects treated with dapagliflozin Exclusion Criteria: - Receipt of any investigational medicinal product within 90 days prior to screening - Use of any OADs (other than SGLT2i in monotherapy or in combination with metformin or DPP4i or pioglitazone as described in the inclusion criteria) within 90 days prior to the day of screening - Use of glucagon-like peptide-1 (GLP-1) receptor agonist (e.g., exenatide or liraglutide) within 90 days prior to the day of screening - Acute decompensation of glycaemic control requiring immediate intensification of treatment to prevent severe metabolic dysregulation (e.g., diabetes ketoacidosis) in the previous 90 days prior to the day of the screening - Subjects presently classified as being in NYHA (New York Heart Association) Class III or IV1 - Renal impairment estimated Glomerular Filtration Rate 60 mL/min/1.73 m2 as per CKD-EPI (Chronic Kidney Disease Epidemiology Collaboration) - Impaired liver function, defined as ALT (alanine aminotransferase) equal to or above 2.5 times upper normal limit at screening - Known or suspected hypersensitivity to trial product(s) or related products

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: None (Open Label)

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: IDegLira	Drug: insulin degludec/liraglutide; IDegLira will be given subcutaneously ( s.c., under the skin) once daily.
Active Comparator: IGlar	Drug: insulin glargine; IGlar will be given subcutaneously ( s.c., under the skin) once daily.

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Change in HbA1c (Glycosylated Haemoglobin)	The mean change from baseline (week 0) in HbA1c values evaluated after 26 weeks of randomised treatment. The results presented included retrieved data at week 26 for subjects who prematurely discontinued the trial product.	Week 0, Week 26

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Change in Body Weight	The mean change from baseline (week 0) in body weight evaluated after 26 weeks of randomised treatment. The results presented included retrieved data at week 26 for subjects who prematurely discontinued the trial product.	Week 0, Week 26
Number of Treatment-emergent Severe or BG (Blood Glucose) Confirmed Symptomatic Hypoglycaemic Episodes	Severe or BG confirmed symptomatic hypoglycaemic episodes were defined as episodes that were severe (subjects who were not able to self-treat) and/or BG confirmed by a plasma glucose values <3.1 mmol/L (56 mg/dL) with accompanied symptoms consistent with hypoglycaemia.	Week 0-26
Insulin Dose, Total Daily Dose (U)	Actual daily total insulin dose (Units) was evaluated after 26 weeks of randomised treatment. The results presented included retrieved data at week 26 for subjects who prematurely discontinued the trial product.	After 26 weeks
Change in Fasting Plasma Glucose (FPG)	Change from baseline (week 0) in FPG was evaluated after 26 weeks of randomised treatment.	Week 0, Week 26
Number of Treatment-emergent Adverse Events	Treatment emergent adverse events (TEAEs) were recorded from week 0 to week 26. TEAE was defined as an event that has onset date on or after the first day of exposure to randomised treatment and no later than 7 days after the last day of randomised treatment.	Week 0-26
Responder (Yes/No) for HbA1c Below 7.0%	The proportion of subjects achieving pre-defined HbA1c targets <7.0% after 26 weeks of randomised treatment. The results presented included retrieved data at week 26 for subjects who prematurely discontinued the trial product.	After 26 weeks
Responder After 26 Weeks (Yes/No) for: HbA1c < 7.0% Without Weight Gain	The proportion of subjects achieving pre-defined HbA1c targets <7.0% without weight gain after 26 weeks of randomised treatment. The results presented included retrieved data at week 26 for subjects who prematurely discontinued the trial product.	After 26 weeks
Responder After 26 Weeks (Yes/No) for: HbA1c < 7.0% Without Treatment-emergent Severe or BG Confirmed Symptomatic Hypoglycaemic Episodes During the Last 12 Weeks of Treatment	The proportion of subjects achieving pre-defined HbA1c targets <7.0% without treatment-emergent severe or BG confirmed symptomatic hypoglycaemic episodes during the last 12 weeks of treatment. The results presented included retrieved data at week 26 for subjects who prematurely discontinued the trial product.	After 26 weeks
Responder After 26 Weeks (Yes/No) for: HbA1c < 7.0% Without Treatment-emergent Severe or BG Confirmed Symptomatic Hypoglycaemic Episodes During the Last 12 Weeks of Treatment and Without Weight Gain	The proportion of subjects achieving pre-defined HbA1c targets <7.0% without treatment-emergent severe or BG confirmed symptomatic hypoglycaemic episodes during the last 12 weeks of treatment and without weight gain. The results presented included retrieved data at week 26 for subjects who prematurely discontinued the trial product.	After 26 weeks
Responder After 26 Weeks (Yes/No) for: HbA1c ≤ 6.5%	The proportion of subjects achieving pre-defined HbA1c targets ≤ 6.5% after 26 weeks of randomised treatment. The results presented included retrieved data at week 26 for subjects who prematurely discontinued the trial product.	After 26 weeks
Responder After 26 Weeks (Yes/No) for: HbA1c ≤ 6.5% Without Weight Gain	The proportion of subjects achieving pre-defined HbA1c targets ≤ 6.5% without weight gain after 26 weeks of randomised treatment. The results are based on retrieved data at week 26 for subjects who prematurely discontinued the trial product.	After 26 weeks
Responder After 26 Weeks (Yes/No) for: HbA1c ≤ 6.5% Without Treatment-emergent Severe or BG Confirmed Symptomatic Hypoglycaemic Episodes During the Last 12 Weeks of Treatment	The proportion of subjects achieving pre-defined HbA1c targets ≤ 6.5%without treatment-emergent severe or BG confirmed symptomatic hypoglycaemic episodes during the last 12 weeks of treatment. The results presented included retrieved data at week 26 for subjects who prematurely discontinued the trial product.	After 26 weeks
Responder After 26 Weeks (Yes/No) for: HbA1c ≤ 6.5% Without Treatment-emergent Severe or BG Confirmed Symptomatic Hypoglycaemic Episodes During the Last 12 Weeks of Treatment and Without Weight Gain	The proportion of subjects achieving pre-defined HbA1c targets ≤ 6.5%without treatment-emergent severe or BG confirmed symptomatic hypoglycaemic episodes during the last 12 weeks of treatment and without weight gain. The results presented included retrieved data at week 26 for subjects who prematurely discontinued the trial product.	After 26 weeks
Change From Baseline After 26 Weeks in Waist Circumference	Mean change from baseline in waist circumference after 26 weeks of randomised treatment.	After 26 weeks
Change From Baseline in Fasting Lipid Profile: Cholesterol	The values of total cholesterol from fasting lipid profile after 26 weeks of randomised treatment.	After 26 weeks
Change From Baseline in Fasting Lipid Profile: Low-density Lipoprotein Cholesterol (LDL Cholesterol)	The values of LDL cholesterol from fasting lipid profile after 26 weeks of randomised treatment.	After 26 weeks
Change From Baseline in Fasting Lipid Profile: High-density Lipoprotein Cholesterol (HDL Cholesterol)	The values of HDL cholesterol from fasting lipid profile after 26 weeks of randomised treatment.	After 26 weeks
Change From Baseline in Fasting Lipid Profile: Very-low-density Lipoprotein Cholesterol (VLDL Cholesterol)	The values of VLDL cholesterol from fasting lipid profile after 26 weeks of randomised treatment.	After 26 weeks
Change From Baseline in Fasting Lipid Profile: Triglycerides	The values of triglycerides from fasting lipid profile after 26 weeks of randomised treatment.	After 26 weeks
Change From Baseline in Fasting Lipid Profile: Free Fatty Acids	The values of free fatty acids from fasting lipid profile after 26 weeks of randomised treatment.	After 26 weeks
Change From Baseline in the 9-point Self-measured Plasma Glucose (SMPG) Profile	Change in 9-point SMPG profile was evaluated after 26 weeks of randomised treatment. SMPG measurements at baseline and week 26 are presented here at the following mentioned time points:1) Before breakfast, 2) 90 mins after the start of Breakfast, 3) Before lunch, 4) 90 mins after the start of lunch, 5) Before dinner, 6) 90 mins after the start of dinner, 7) At bedtime, 8) At 4 AM, 9) Before breakfast the following day.	After 26 weeks
Change From Baseline in Self-measured Plasma Glucose (SMPG) 9-point Profile: Mean of the 9-point Profile	Change in mean of the 9-point profile SMPG was evaluated after 26 weeks of randomised treatment. 9-point profile SMPG was measured at the following mentioned time points:1) Before breakfast, 2) 90 mins after the start of Breakfast, 3) Before lunch, 4) 90 mins after the start of lunch, 5) Before dinner, 6) 90 mins after the start of dinner, 7) At bedtime, 8) At 4 AM, 9) Before breakfast the following day.	After 26 weeks
Change From Baseline in SMPG 9-point Profile: Prandial Plasma Glucose Increments (From Before Meal to 90 Min After Breakfast, Lunch and Dinner). The Mean Increment Over All Meals Will be Derived as the Mean of All Available Meal Increments	Mean prandial plasma glucose increments for each meal (from before meal to 90 min after breakfast, lunch and dinner) was evaluated after 26 weeks of randomised treatment. The mean increment over all meals was derived as the mean of all available meal increments are presented here.	After 26 weeks
Change From Baseline in Systolic Blood Pressure	Change from baseline (week 0) in systolic blood pressure (BP) was evaluated after 26 weeks of randomised treatment.	After 26 weeks
Change From Baseline in Diastolic Blood Pressure	Change from baseline (week 0) in diastolic blood pressure was evaluated after 26 weeks of randomised treatment.	After 26 weeks
Number of Treatment-emergent Nocturnal Severe or BG Confirmed Symptomatic Hypoglycaemic Episodes During 26 Weeks	Number of treatment-emergent nocturnal severe or BG confirmed symptomatic hypoglycaemic episodes (00:01-05:59 - inclusive) during 26 weeks of randomised treatment.	Week 0-26
Number of Treatment-emergent Hypoglycaemic Episodes According to ADA Definition During 26 Weeks	American Diabetes Association (ADA) classification of hypoglycaemic episodes: 1)Severe: Requiring assistance of another person to actively administer carbohydrate/glucagon/take other corrective actions. PG levels may not be available during an event, but neurological recovery following return of PG to normal is considered sufficient evidence that event was induced by a low PG level. 2) Documented symptomatic: PG ≤3.9 mmol/L with symptoms. 3) Asymptomatic: PG ≤3.9 mmol/L without symptoms. 4) Probable symptomatic: No measurement with symptoms. 5) Pseudo: PG >3.9 mmol/L with symptoms. 6) Unclassifiable.	Week 0-26
Change From Baseline in Clinical Evaluation After 26 Weeks: Electrocardiogram (ECG)	Reported results are ECG findings at screening and week 26 of randomised treatment. Since the values measured at the baseline (week 0) were not collected, the screening data (week -2, which is <= 2 weeks before baseline) is presented here. The findings are categorised as: 1) Normal. 2) Abnormal (not clinically significant [NCS]). 3) Abnormal (clinically significant [CS]). 4) Missing.	After 26 weeks
Change From Baseline in Clinical Evaluation After 26 Weeks: Eye Examination: Fundoscopy/Fundus Photography	Reported results are fundus photography/fundoscopy (for both left and right eye) findings at screening and week 26 of randomised treatment. Since the values measured at the baseline (week 0) were not collected, the screening data (week -2, which is <= 2 weeks before baseline) is presented here. The findings are categorised as: 1) Normal. 2) Abnormal (not clinically significant [NCS]). 3) Abnormal (clinically significant [CS]). 4) Missing.	After 26 weeks
Change From Baseline in Clinical Evaluation After 26 Weeks: Pulse Rate	Change from baseline (week 0) in pulse rate was evaluated after 26 weeks of randomised treatment.	After 26 weeks
Change From Baseline in Patient Reported Outcomes (PROs) After 26 Weeks: Summary Scores of Medical Outcomes Study 36-item Short Form (SF-36v2)	The Short Form (SF)-36v2™ patient reported outcomes (PRO) questionnaire was used to assess the subject's overall health related quality of life (HRQoL). PRO questionnaire (SF-36v2™) measured the HRQoL which contains 36 items covering 8 domains of physical and mental health status. The raw scale scores from the SF-36 were transformed to a 0-100 scale scores (where higher scores indicated a better health status) which is further converted to norm-based scores using a T-score transformation in order to obtain a direct interpretation in relation to the distribution of the scores in the 2009 reference population . The total/overall (SF-36v2™) scores for physical and mental health from baseline to week 26 are presented here.	After 26 weeks
Change From Baseline in Patient Reported Outcomes (PROs) After 26 Weeks: Summary Scores of Treatment Related Impact Measure for Diabetes (TRIM-D)	The patient reported outcomes are calculated based on TRIM-D questionnaire. The TRIM-D questionnaire consists of 5 sub-domains (treatment burden, daily life, diabetes management, compliance and psychological health), where each question is scored to a 1-5-point scale with a higher score indicating a better health state (less negative impact). Mean TRIM-D domain scores and the total scores are later transformed to a 0-100 scale for analysis. Summary scores from baseline and week 26 for total/overall scores are presented here.	After 26 weeks

Collaborators and Investigators

• Sponsor: Novo Nordisk A/S

Publications and helpful links

General Publications

• Philis-Tsimikas A, Billings LK, Busch R, Portillo CM, Sahay R, Halladin N, Eggert S, Begtrup K, Harris S. Superior efficacy of insulin degludec/liraglutide versus insulin glargine U100 as add-on to sodium-glucose co-transporter-2 inhibitor therapy: A randomized clinical trial in people with uncontrolled type 2 diabetes. Diabetes Obes Metab. 2019 Jun;21(6):1399-1408. doi: 10.1111/dom.13666. Epub 2019 Apr 4.

Helpful Links

• Clinical Trials at Novo Nordisk

Study record dates

Study Major Dates

• Study Start (Actual): May 23, 2016
• Primary Completion (Actual): September 26, 2017
• Study Completion (Actual): October 23, 2017

Study Registration Dates

• First Submitted: May 13, 2016
• First Submitted That Met QC Criteria: May 13, 2016
• First Posted (Estimate): May 16, 2016

Study Record Updates

• Last Update Posted (Actual): August 11, 2020
• Last Update Submitted That Met QC Criteria: August 10, 2020
• Last Verified: August 1, 2020

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Glucose Metabolism Disorders; Metabolic Diseases; Endocrine System Diseases; Diabetes Mellitus; Diabetes Mellitus, Type 2; Hypoglycemic Agents; Physiological Effects of Drugs; Hormones; Hormones, Hormone Substitutes, and Hormone Antagonists; Incretins; Insulin; Insulin, Globin Zinc; Liraglutide; Insulin Glargine; Xultophy
• Other Study ID Numbers: NN9068-4229; 2015-001596-48 (EudraCT Number); U1111-1168-9343 (Other Identifier: WHO); REec-2016-2248 (Other Identifier: REec)